Federal Register / Vol. 71, No. 169 / Thursday, August 31, 2006 / Notices 51837 

1. L Berra et al. Antibacterial-coated 

tracheal tubes cleaned with the Mucus 

Shaver: A novel method to retain longterm bactericidal activity of coated 

tracheal tubes. Intensive Care Med. 2006 

Jun;32(6):888–893. Epub 2006 Apr 19, 

doi: 10.1007/s00134–006–0125–6. 

2. T Kolobow et al. Novel system for 

complete removal of secretions within 

the endotracheal tube: the Mucus 

Shaver. Anesthesiology. 2005 

May;102(5):1063–1065. 

3. L Berra et al. Evaluation of 

continuous aspiration of subglottic 

secretion in an in vivo study. Crit Care 

Med. 2004 Oct;32(10):2071–2078. 

4. R Trawoger et al. Intratracheal 

pulmonary ventilation keeps tracheal 

tubes clean without impairing 

mucociliary transport. Scand J Clin Lab 

Invest. 2002;62(5):351–356. 

Patent Status: U.S. Patent Application 

No. 11/081,420 filed 15 Mar 2005 (HHS 

Reference No. E–074–2005/0–US–01); 

International Patent Application PCT/ 

US2006/009166 filed 14 Mar 2006 (HHS 

Reference No. E–074–2005/0–PCT–02). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Michael A. 

Shmilovich, Esq.; 301/435–5019; 

shmilovm@mail.nih.gov. 

Collaborative Research Opportunity: 

The NHLBI Pulmonary Critical Care 

Medicine Branch is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize the endotracheal tube 

mucus cleaning device and related 

laboratory interests. Please contact 

Marianne Lynch at 301–594–4094 or 

lynchm@nhlbi.nih.gov for more 

information. 

Mucus Shaving Apparatus for 

Endotracheal Tubes 

Description of Technology: HHS seeks 

parties interested in manufacturing and 

commercializing an endotracheal tube 

cleaning apparatus for insertion into the 

inside of the endotracheal tube of a 

patient to shave away mucus deposits. 

This cleaning apparatus comprises a 

flexible central tube with an inflatable 

balloon at its distal end. Affixed to the 

inflatable balloon are one or more 

silicone rubber shaving rings, each 

having a squared leading edge to shave 

away mucus accumulations implicated 

in bacterial accumulation. In operation, 

the un-inflated cleaning apparatus is 

inserted into the endotracheal tube until 

its distal end is properly aligned with 

the distal end of the endotracheal tube. 

After proper alignment, the balloon is 

inflated by a suitable inflation device 

(e.g., a syringe) until the balloon’s 

shaving rings are pressed against the 

inside surface of the endotracheal tube. 

The cleaning apparatus is then pulled 

out of the endotracheal tube and in the 

process the balloon’s shaving rings 

shave off the mucus deposits from the 

inside of the endotracheal tube. 

Inventors: Theodor Kolobow and 

Lorenzo Berra (NHLBI). 

Publication: T Kolobow et al. Novel 

system for complete removal of 

secretions within the endotracheal tube: 

the Mucus Shaver. Anesthesiology. 2005 

May;102(5):1063–1065. 

Patent Status: U.S. Patent No. 

7,051,737 issued 05 Feb 2004 (HHS 

Reference No. E–061–2004/0–US–01). 

Related Technology: PCT Application 

No. PCT//US2005/003395 filed 04 Feb 

2005, which published as WO 2005/ 

076895 on 25 Aug 2005 (HHS Reference 

No. E–061–2004/1–PCT–01). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Michael 

Shmilovich, Esq.; 301/435–5019; 

shmilovm@mail.nih.gov. 

Collaborative Research Opportunity: 

The NHLBI Pulmonary Critical Care 

Medicine Branch is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize the endotracheal tube 

apparatus and related laboratory 

interests. Please contact Marianne 

Lynch at 301–594–4094 or 

lynchm@nhlbi.nih.gov for more 

information. 

Dated: August 25, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–7330 Filed 8–30–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Molecules for Studying Cellular 

Immune Responses to Vaccines and 

Therapeutics 

Description of Technology: HLA 

molecules are indispensable and 

invaluable tools for efficient vaccine 

research and development. Infectious 

diseases are the second leading cause of 

death among adults and the most 

prominent cause of death in infants and 

children worldwide. Thus, rapid 

availability of prophylactic vaccines for 

cancers and infectious diseases such as 

HIV, HPV, influenza and diarrheal and 

respiratory diseases is a world-wide 

health concern. 

Available for licensing is a large 

variety of cell lines, each expressing a 

particular HLA molecule and the 

plasmids encoding them, including 

soluble HLAs. This technology has 

broad application for development of 

vaccines and immunotherapeutics. HLA 

molecules can be used to characterize 

HLA-peptide binding and elucidate the 

process of both antigen and tumor cell 

peptide-processing and presentation. In 

addition to wild-type HLA molecules, 

available for licensing are HLAs 

containing point-mutations in the 

peptide binding regions. The mutated 

HLAs can be used to evaluate key 

peptide interactions. Additionally, 

soluble HLA molecules are useful for 

elucidating the structural details of 

HLAs and HLA-peptide complexes 

through crystallographic studies, which 

can be used to aid in vaccine design. 

Thus, the present technology has the 

potential to lend insight into immune 

recognition and identification of 

immunogenic epitopes for the 

systematic design of peptide and protein 

subunit vaccines for cancers and 

infectious diseases. Furthermore, this 

technology has application in the 

development of therapies for 

autoimmune and related immunological 

diseases, including those associated 

with organ transplantation. 

Applications: (1) Identification/ 

Quantification of T cell responses to 

specific antigens including vaccine 

antigens; (2) Identification of T cell 


erjones on PROD1PC72 with NOTICES
51838 Federal Register / Vol. 71, No. 169 / Thursday, August 31, 2006 / Notices 

responses in patients with autoimmune 

diseases; (3) Development of vaccines 

candidates for cancer and infectious 

diseases; (4) Organ transplant 

diagnostics and immunotherapeutics. 

Inventors: William Biddison, Richard 

Turner, Susan Gagnon (NINDS). 

Relevant Publications: 

1. TK Baxter, SJ Gagnon, RL DavisHarrison, JC Beck, AK Binz, RV Turner, 

WE Biddison. Strategic mutations in the 

class I major histocompatibility complex 

HLA–A2 independently affect both 

peptide binding and T cell receptor 

recognition. J. Biol. Chem. 2004 Jul 9; 

279(28):29175–29184. 

2. BM Baker, RV Turner, SJ Gagnon, 

DC Wiley, WE Biddison. Identification 

of a crucial energetic footprint on the 

alpha1 helix of human 

histocompatibility leukocyte antigen 

(HLA)–A2 that provides functional 

interactions for recognition by tax 

peptide/HLA–A2-specific T cell 

receptors. J. Exp. Med. 2001 Mar 5; 

193(5):551–562. 

Patent Status: HHS Reference Nos. E–

251–2006/0 and E–251–2006/1—

Biological Materials. 

Licensing Status: Available for 

licensing through Biological Materials 

License Agreements. 

Licensing Contact: Susan Ano, Ph.D.; 

301/435–5515; anos@mail.nih.gov. 

Neutralizing Monoclonal Antibodies to 

Botulinum Neurotoxin A 

Description of Technology: Available 

for licensing from the NIH are two 

chimpanzee-derived monoclonal 

antibodies (mAbs) against botulinum 

neurotoxin type A (BoNT/A). These 

mAbs can be developed for prevention, 

therapy, or diagnosis of BoNT/A. Use of 

this technology represents a significant 

improvement over the existing therapy 

of supportive care and treatment with 

equine antitoxin polyclonal antibodies. 

Potential Applications of Technology: 

(1) Emergency prophylaxis against 

BoNT/A outbreak (natural or 

biodefense-related); (2) Therapeutic 

against BoNT/A; (3) Rapid Diagnosis of 

BoNT/A; (4) Therapeutic against 

overdosage of BoNT/A as used in 

clinical treatments. 

Advantages of Existing Therapies: (1) 

No anticipated side effects compared to 

currently utilized equine antitoxin 

polyclonal antibodies; (2) Monoclonal 

instead of polyclonal. 

Inventors: Robert H. Purcell et al. 

(NIAID). 

Patent Status: HHS Reference No. E–

180–2006/0—Research Tool. 

Licensing Status: Available for nonexclusive licensing. 

Licensing Contact: Susan Ano, Ph.D.; 

301/435–5515; anos@mail.nih.gov. 

Dated: August 25, 2006. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 06–7331 Filed 8–30–06; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Initial Review Group, Subcommittee 

F—Manpower & Training, NCI F—Initial 

Review of K01 and T32 Applications. 

Date: September 26–27, 2006. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Holiday Inn Georgetown, 2101 

Wisconsin Avenue, NW., Washington, DC 

20007. 

Contact Person: Lynn M. Amende, PhD, 

Scientific Review Administrator, Resources 

and Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd., Room 8105, 

Bethesda MD 20892, 301–451–4759, 

amendel@mail.nih.go. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: August 25, 2006. 

Anna Snouffer, 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 06–7336 Filed 8–30–06; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Deafness and 

Other Communication Disorders; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, R03 

Chemosense Scientific Review Panel. 

Date: October 5, 2006. 

Time: 11 a.m. to 2 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Sheo Singh, PhD, 

Scientific Review Administrator, Scientific 

Review Branch, Division of Extramural 

Activities, Executive Plaza South, Room 

400C, 6120 Executive Blvd., Bethesda, MD 

20892; 301–496–8683; singhs@nidcd.nih.gov. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, R03 Voice 

and Language Scientific Review Meeting. 

Date: October 5, 2006. 

Time: 1 p.m. to 4 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Shiguang Yang, PhD, 

DVM, Scientific Review Administrator, 

Division of Extramural Activities, NIDCD, 

NIH, 6120 Executive Blvd., Bethesda, MD 

20892; 301–496–8683. 

Name of Committee: National Institute on 

Deafness and Other Communication 

Disorders Special Emphasis Panel, R03 

Hearing and Balance Scientific Review 

Meeting. 

Date: October 6, 2006. 

Time: 11 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6120 

Executive Blvd., Rockville, MD 20852, 

(Telephone Conference Call). 

Contact Person: Shiguang Yang, PhD, 

DVM, Scientific Review Administrator, 


erjones on PROD1PC72 with NOTICES